Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Each of these walkways is bordered by London plane (Platanus × hispanica) trees, which contribute to the park's European feel. In addition, numerous statues are scattered throughout the park. A raised terrace on the eastern side of the lawn, which dates to the construction of the library's main branch, is paved with gray flagstones and red brick. Its centerpiece is the William Cullen Bryant Memorial, which is raised on a pedestal of its own. A restroom structure is located at the northern border of the park along 42nd Street. A carousel, installed in 2002, is located at the park's southern border. The park is served by the New York City Subway's 7, <7>, B, D, F, <F>, and M trains at 42nd Street–Bryant Park/Fifth Avenue station, entrances to which are located on the northern and western borders of the park, as well as MTA Regional Bus Operations' M1, M2, M3, M4, M5, M7, M42, M55 and Q32 routes.
== Genetics == Fibrous protein, long filamentous protein molecule that forms one of the two main classes of tertiary structure protein Fusion protein, protein created through genetic engineering from two or more proteins Globular protein, one of the two main protein classes Protein family, group of evolutionarily related proteins Protein methods, techniques used to study proteins Protein subunit, single protein molecule that assembles with other protein molecules to form a multimeric or oligomeric protein Regulatory protein, term used in genetics to describe a protein involved in regulating gene expression
== Select publications == Müller, Thomas; Badu-Tawiah, Abraham; Cooks, R. Graham (2012). "Accelerated Carbon-Carbon Bond-Forming Reactions in Preparative Electrospray". Angewandte Chemie International Edition. 51 (47): 11832–11835. doi:10.1002/anie.201206632. ISSN 1521-3773. PMID 23042619. Badu-Tawiah, Abraham K.; Eberlin, Livia S.; Ouyang, Zheng; Cooks, R. Graham (2016). "Faculty Opinions recommendation of Chemical aspects of the extractive methods of ambient ionization mass spectrometry". Annual Review of Physical Chemistry. 64: 481–505. doi:10.1146/annurev-physchem-040412-110026. PMID 23331308. Damon, Deidre E.; Davis, Kathryn M.; Moreira, Camila R.; Capone, Patricia; Cruttenden, Riley; Badu-Tawiah, Abraham K. (10 February 2016). "Direct Biofluid Analysis Using Hydrophobic Paper Spray Mass Spectrometry". Analytical Chemistry. 88 (3): 1878–1884. doi:10.1021/acs.analchem.5b04278.s001. PMID 26730614.
Narrated by Paul Barry, produced by Daryl Karp, directed by Richard Smith, an Australian production, made by ABC 25 September Cleared for Take-off, the years leading to the first flight of the Boeing 777, planned for May 1995; testing the Boeing 777 APU in cold weather in Alaska; Boeing put £5bn into the testing; Alan Mulally, head of the 777 team; the evangelical management process of 'Working Together', to avoid secrecy; Ronald Ostrowski, director of engineering on the 777; the engines cost 20% of the total cost; Granville Frazier of propulsion; the ETOPS standard for twin-engined aircraft; Chester Ekstrand; the first ever 747 is fitted with a 777 testbed engine; the Pratt Whitney test rig at the Aero-propulsion Systems Test Facility at Tullahoma, Tennessee; Baldey Mehta of the 777 engine; John Cashman, the chief 777 test pilot; the 777 engine testbed has an engine surge, on take off; Thomas Davenport, head of the 777 program for Pratt Whitney; Rocky Thomas of Propulsion; the 777 fuselage is pressurised in January 1994, for the first time from 5 psi to 12 psi; Philip M. Condit; Neil Standal of the fabrication division; Jim McWha of flight testing; Lyle Eveland, head of factory operations; the 777 has its first flight on 12 June 1994, to test the aircraft stability; Frank Shrontz, head of Boeing.
Sources: en.wikipedia.org
== Past predictions == In May 1998, George Kennan described the US Senate vote to expand NATO to include Poland, Hungary, and the Czech Republic as "the beginning of a new cold war", and predicted that "the Russians will gradually react quite adversely and it will affect their policies". In 2001, foreign policy and security experts James M. Lindsay and Ivo Daalder described counterterrorism as the "new Cold War". British journalist Edward Lucas wrote in February 2008 that a new cold war between Russia and the West had already begun.
Renee and her son Sekou walk Jasmine down the aisle at her wedding with Crosby. Renee lives with Crosby, Jasmine, and Jabbar briefly when she loses her job, but moves out after a disagreement on how they discipline Jabbar. Renee insists that baby Aida should be baptized, and holds a baptism brunch at her place. She gets along well with Camille, and at the pre-baptism dinner at Zeek and Camille's house, says she always enjoys dinners that Camille holds. Gordon Flint (William Baldwin) was Adam's boss until he sold the company. When Sarah became an intern at Adam's company, she and Gordon became romantically involved, which caused friction between Adam and Sarah. Gordon is invited by Sarah to the Braverman Thanksgiving dinner, but that morning, when telling Adam he sold the company, Adam asks him not to come to the dinner. Gordon comes anyway, and at the football game that afternoon, tensions between Adam and Gordon come to a head. Mike (Kevin Alejandro), aka "Forklift Mike", drives a forklift at T&S Footwear. Mike recommends a band for Sarah to take Amber and Kelsey to see, at a club where Mike knows the man at the door. Alex (Michael B. Jordan) is Haddie's on again, off again boyfriend, whom she met while she volunteering at the food bank he currently manages. He is a recovering alcoholic and three years older than Haddie, so Haddie's parents initially disapprove of the relationship. Cory Smith (Anthony Carrigan) is Adam's new boss when Gordon sells the company. His youth and radical approach to business are disconcerting to Adam.
=== Modern Applications and Research === Recent scientific advancements have led to a great interest in insect derived pharmaceuticals. Researchers are investigating the potential of insect peptides as alternatives to conventional antibiotics, given their effectiveness against drug resistant pathogens. Additionally bioengineering techniques are being explored to enhance the medicinal properties of insect compounds with applications in tissue regeneration, cancer therapy, and antimicrobial resistance management.
dihydrothymine dehydrogenase dihydrouracil dehydrogenase (NADP+) 4,5-dihydrothymine: oxidoreductase DPD DHPDH dehydrogenase, dihydrouracil (nicotinamide adenine dinucleotide, phosphate) DHU dehydrogenase hydropyrimidine dehydrogenase dihydropyrimidine dehydrogenase (NADP+)
Membrane receptor proteins relay signals between the cell's internal and external environments. Transport proteins move molecules and ions across the membrane. They can be categorized according to the Transporter Classification database. Membrane enzymes may have many activities, such as oxidoreductase, transferase or hydrolase. Cell adhesion molecules allow cells to identify each other and interact. For example, proteins involved in immune response The localization of proteins in membranes can be predicted reliably using hydrophobicity analyses of protein sequences, i.e. the localization of hydrophobic amino acid sequences.
Sources: en.wikipedia.org
== Examples == Only two elements are liquid at standard conditions for temperature and pressure: mercury and bromine. Four more elements have melting points slightly above room temperature: francium, caesium, gallium and rubidium. Pure substances that are liquid under normal conditions include water, ethanol and many other organic solvents. Liquid water is of vital importance in chemistry and biology, and it is necessary for all known forms of life. Inorganic liquids in this category include inorganic nonaqueous solvents and many acids. Mixtures that are liquid at room temperature include alloys such as galinstan (a gallium-indium-tin alloy that melts at −19 °C or −2 °F) and some amalgams (alloys involving mercury). Certain mixtures, such as the sodium-potassium metal alloy NaK, are liquid at room temperature even though the individual elements are solid under the same conditions (see eutectic mixture). Everyday liquid mixtures include aqueous solutions like household bleach, other mixtures of different substances such as mineral oil and gasoline, emulsions like vinaigrette or mayonnaise, suspensions like blood, and colloids like paint and milk. Many gases can be liquefied by cooling, producing liquids such as liquid oxygen, liquid nitrogen, liquid hydrogen and liquid helium. However, not all gases can be liquefied at atmospheric pressure. Carbon dioxide, for example, solidifies directly into dry ice rather than becoming a liquid, and it can only be liquified at pressures above 5.1 atm. Most liquids solidify as the temperature is decreased further.
== Biochemistry == 3-Methylhistidine is a metabolic product that is produced in the body via the enzymatic methylation of histidine during peptide bond synthesis and the methylation of actin and myosin.
== See also == Calorimeter Clinical chemistry Environmental chemistry Ion beam analysis List of chemical analysis methods Important publications in analytical chemistry List of materials analysis methods Measurement uncertainty Metrology Microanalysis Nuclear reaction analysis Quality of analytical results Radioanalytical chemistry Rutherford backscattering spectroscopy Sensory analysis - in the field of Food science Virtual instrumentation Working range
One of the only human self-reports on a cryobranding in the scientific literature relates "a sharp tingling sensation followed by numbness" as the subject used a small cryobrand to mark his own forearm. There is little information regarding the safety or long-term effectiveness of human cryobranding.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.